Researchers at UVA Health discovered that particular antibodies in COVID-19 patients, which behave like enzymes, might be responsible for severe and long-lasting signs, recommending brand-new targeted treatment approaches.Researchers at UVA Health have actually revealed a possible description for some of the most confusing aspects of COVID-19 and long COVID. These unexpected insights might pave the method for novel treatments targeting the tough acute effects of COVID-19, long COVID, and potentially other viruses.Researchers led by UVAs Steven L. Zeichner, MD, PhD, found that COVID-19 may prompt some peoples bodies to make antibodies that act like enzymes that the body naturally uses to manage essential functions– blood pressure. If abzymes with rogue activities are also accountable for some of the features of long COVID, doctors might target the abzymes to deal with the tough and in some cases mysterious symptoms of COVID-19 and long COVID at the source, rather of merely treating the downstream symptoms. It likewise might describe rare side results of COVID-19 vaccination.To figure out if antibodies might be having unexpected effects in COVID clients, Zeichner and his partners analyzed plasma samples gathered from 67 volunteers with moderate or extreme COVID on or around day 7 of their hospitalization.”Reference: “ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 patients” by Yufeng Song, Regan Myers, Frances Mehl, Lila Murphy, Bailey Brooks, Jeffrey M. Wilson, Alexandra Kadl, Judith Woodfolk and Steven L. Zeichner, 19 March 2024, mBio.DOI: 10.1128/ mbio.00541-24The abzyme research was supported by UVA, consisting of the Manning Fund for COVID-19 Research at UVA; the Ivy Foundation; the Pendleton Laboratory Fund for Pediatric Infectious Disease Research; a College Council Minerva Research Grant; the Coulter Foundation; and the National Institutes of Healths National Institute of Allergy and Infection Diseases, grant R01 AI176515.
Researchers at UVA Health discovered that specific antibodies in COVID-19 patients, which act like enzymes, may be responsible for serious and long-lasting signs, recommending brand-new targeted treatment approaches.Researchers at UVA Health have revealed a prospective explanation for some of the most puzzling aspects of COVID-19 and long COVID. These unexpected insights may pave the way for unique treatments targeting the tough severe impacts of COVID-19, long COVID, and possibly other viruses.Researchers led by UVAs Steven L. Zeichner, MD, PhD, discovered that COVID-19 may prompt some peoples bodies to make antibodies that act like enzymes that the body naturally uses to regulate essential functions– blood pressure.”Reference: “ACE-2-like enzymatic activity is associated with immunoglobulin in COVID-19 clients” by Yufeng Song, Regan Myers, Frances Mehl, Lila Murphy, Bailey Brooks, Jeffrey M. Wilson, Alexandra Kadl, Judith Woodfolk and Steven L. Zeichner, 19 March 2024, mBio.DOI: 10.1128/ mbio.00541-24The abzyme research was supported by UVA, including the Manning Fund for COVID-19 Research at UVA; the Ivy Foundation; the Pendleton Laboratory Fund for Pediatric Infectious Disease Research; a College Council Minerva Research Grant; the Coulter Foundation; and the National Institutes of Healths National Institute of Allergy and Infection Diseases, grant R01 AI176515.
